Treatment with sofosbuvir/velpatavir for 12 weeks is safe and effective in patients with hepatitis C (HCV) recurrence after a liver transplant, according to results published in the Journal of Hepatology.
A multicenter, open-label study (ClinicalTrials.gov Identifier: NCT02781571) included participants infected with HCV genotype 1, 2, 3, and 4 (n=79). Inclusion criteria included having received a liver transplant or combined liver-kidney transplant at least 3 months prior to study entry with no clinical signs of rejection in the past 3 months. Patients without cirrhosis or with compensated cirrhosis were eligible for inclusion.
Each participant was treated with sofosbuvir 400 mg and velpatasvir 100 mg daily for 12 weeks.